Skip to main content

Mark L. McLaughlin, Ph.D.

Professor of Medicinal Chemistry

Chemistry Adjunct Professor


PB.S., Chemistry, Christian Brothers University 
Ph.D., Organic Chemistry, Georgia Institute of Technology. 
Postdoctoral appointments at Rice and Ohio State Universities

McLaughlin’s research group is pursuing anticancer drug discovery and development focused on protein-protein interaction inhibitor design, molecularly targeted radiotherapy, and molecularly targeted immunotherapy for the treatment/cure of targeted cancers.


Propagation of Information About Preexposure Prophylaxis (PrEP) for HIV Prevention Through Twitter.
McLaughlin ML, Hou J, Meng J, Hu CW, An Z, Park M, Nam Y.
Health Commun. 2016 Aug;31(8):998-1007. doi: 10.1080/10410236.2015.1027033. Epub 2016 Jan 12.

MTI-101 (cyclized HYD1) binds a CD44 containing complex and induces necrotic cell death in multiple myeloma.
Gebhard AW, Jain P, Nair RR, Emmons MF, Argilagos RF, Koomen JM, McLaughlin ML, Hazlehurst LA.
Mol Cancer Ther. 2013 Nov;12(11):2446-58. doi: 10.1158/1535-7163.MCT-13-0310. Epub 2013 Sep 18.  

Tetra-methyl anthracene-2,3,6,7-tetra-carboxyl-ate-tetra-methyl 9,10-dihydro-9,10-dioxoanthracene-2,3,6,7-tetra-carboxyl-ate (1/1).
Drake BL, Morris JL, McLaughlin ML, Fronczek FR, Watkins SF. Acta Crystallogr Sect E Struct Rep Online. 2012 Aug 1;68(Pt 8):o2540-1. doi: 10.1107/S1600536812032424. Epub 2012 Jul 25. 

Acquisition of resistance toward HYD1 correlates with a reduction in cleaved α4 integrin expression and a compromised CAM-DR phenotype.
Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE, Hazlehurst LA. Mol Cancer Ther. 2011 Dec;10(12):2257-66. doi: 10.1158/1535-7163.MCT-11-0149. Epub 2011 Oct 6. 

Phelan WA, Ngu-Schwemlein M, Fronczek FR, McLaughlin ML, Watkins SF. Acta Crystallogr Sect E Struct Rep Online. 2011 Apr 1;67(Pt 4):o757. doi: 10.1107/S1600536811006623. Epub 2011 Mar 2.  

Facile iterative synthesis of 2,5-terpyrimidinylenes as nonpeptidic alpha-helical mimics.
Anderson L, Zhou M, Sharma V, McLaughlin JM, Santiago DN, Fronczek FR, Guida WC, McLaughlin ML.
J Org Chem. 2010 Jun 18;75(12):4288-91. doi: 10.1021/jo100272d.  

Efficient assembly of 2,5,6-substituted pyrimidines via MgI(2)-mediated Morita-Baylis-Hillman reaction.
Sharma V, McLaughlin ML. J Comb Chem. 2010 May 10;12(3):327-31. doi: 10.1021/cc100001e. 

(S)-(Z)-Methyl 2-[2,3-bis-(benzyl-oxy-carbon-yl)guanidino]-4-methyl-penta-no-ate.
Fronczek CF, Kil H, McLaughlin ML, Fronczek FR.
Acta Crystallogr Sect E Struct Rep Online. 2010 Dec 4;67(Pt 1):o27-8. doi: 10.1107/S1600536810050130. 

Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells.
Kazi A, Lawrence H, Guida WC, McLaughlin ML, Springett GM, Berndt N, Yip RM, Sebti SM.
Cell Cycle. 2009 Jun 15;8(12):1940-51. Epub 2009 Jun 20. 

Identification of a disruptor of the MDM2-p53 protein-protein interaction facilitated by high-throughput in silico docking.
Lawrence HR, Li Z, Yip ML, Sung SS, Lawrence NJ, McLaughlin ML, McManus GJ, Zaworotko MJ, Sebti SM, Chen J, Guida WC.
Bioorg Med Chem Lett. 2009 Jul 15;19(14):3756-9. doi: 10.1016/j.bmcl.2009.04.124. Epub 2009 May 3.